GENELUX Corp

Business Summary

PART I A. Overview Genelux is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat tumor types. Our clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patients tumor neoantigens. Importantly, our oncolytic immunotherapy product candidates are off-the-shelf personalized immunotherapies....

Next Earnings

Q2 FY2026 — expected 2026-09-13

Key Facts from Earnings Calls

Annual Reports (10-K)

Quarterly Reports (10-Q)

Recent Current Reports (8-K)

63 total filings indexed. 40 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

Company Identity

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API: